Reviewer's report

Title: Choroidal Structural Changes Correlate with Severity of Diabetic Retinopathy in Diabetes Mellitus

Version: 1 Date: 24 Apr 2019

Reviewer: Taiji Sakamoto

Reviewer's report:

1. Introduction and through the text

Although Agrawal et al proposed choroidal vascular index (CVI) as choroidal vascular parameter, this nomenclature is not approved by all researchers. Therefore, it is strongly recommended to use the term, "ratio of choroidal luminal area".

Page, Line 46

After the image segmentation technique proposed by Sonoda et al.[11,12] similar analysis was followed by Agrawal et al.[13]. They measured the ratio of choroidal luminal area in OCT image and it is used as a parameter of choroidal structure.

2. The systemic treatment should be described in each group. (eg number of cases using insulin)

3. History of ocular treatment in each group should be described as well. It is hard to believe that none of them was treated by laser photocoagulation.
Are the methods appropriate and well described?
Yes

Does the work include the necessary controls?
Yes

Are the conclusions drawn adequately supported by the data shown?
Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
Not relevant to this manuscript

Quality of written English
Needs some language corrections before being published

Declaration of competing interests
1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

Yes. I received honorarium from Santen, Bayer, Novartis and Alcon.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal